Teva Pharmaceutical Reports 2% Revenue Growth to $3.982 Billion in Q1 2026

Teva Pharmaceutical Industries Ltd. reported its financial results for the first quarter of 2026, revealing a net revenue of $3.982 billion, a 2% increase from $3.891 billion in the same period last year. The company’s gross profit rose to $1.972 billion, up from $1.877 billion, resulting in a gross profit margin of 49.5%, compared to 48.2% in the prior year. Operating income for the quarter was $652 million, significantly higher than the $519 million reported in the first quarter of 2025. This increase in profitability was attributed to lower intangible asset impairments and higher gross profit, despite rising selling and marketing expenses.

In terms of segment performance, Teva's U.S. segment generated revenues of $1.534 billion, remaining flat compared to the previous year, while the Europe segment saw a 12% increase in revenues to $1.340 billion. The International Markets segment, however, experienced a decline, with revenues falling 10% to $524 million, primarily due to the divestment of its business venture in Japan. The company noted that exchange rate fluctuations positively impacted revenues by $219 million compared to the first quarter of 2025.

Teva's strategic developments included the announcement of a definitive agreement to acquire Emalex Biosciences for $700 million, which is expected to close in the third quarter of 2026, pending regulatory approvals. This acquisition aims to enhance Teva's innovative product pipeline, particularly in the treatment of Tourette syndrome. Additionally, Teva has been actively pursuing its "Pivot to Growth" strategy, focusing on expanding its innovative and biosimilar medicines pipeline while optimizing its operational efficiencies.

Operationally, Teva reported a decrease in research and development (R&D) expenses to $222 million, down 10% from the previous year, reflecting a strategic shift in focus. The company’s total employee-related obligations decreased to $555 million, down from $739 million at the end of 2025, primarily due to performance incentive payments. As of March 31, 2026, Teva's total debt was $16.627 billion, a slight decrease from $16.807 billion at the end of 2025, with cash and cash equivalents increasing to $3.741 billion.

Looking ahead, Teva anticipates continued challenges from geopolitical tensions and market conditions, particularly in the context of its global operations. The company remains committed to its strategic initiatives aimed at driving growth and improving operational efficiency, while also navigating the complexities of the pharmaceutical market landscape.